SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
  • 2
    Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 1030
  • 3
    Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99166
  • 4
    Heidenreich H, Aus G, Abbou CC et al. Guidelines on prostate cancer. European Association of Urology, 2007. Available at: http://www.uroweb.org/fileadmin/tx_eauguidelines/Prostate%20Cancer.pdf
  • 5
    Sasagawa I, Kubota Y, Nakada T et al. Influence of LHRH analogues on serum levels of PAP and PSA in patients with metastatic carcinoma of the prostate. Int J Urol Nephrol 1998; 30: 74553
  • 6
    Oefelein MG, Feng A, Scolieri MJ et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000; 56: 10214
  • 7
    Seidenfeld J, Samson DJ, Hasselblad V et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132: 56677
  • 8
    Heidenreich A, Aus G, Abbou CC et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 6880
  • 9
    Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001; 58 (Suppl. 1): 59
  • 10
    Van Poppell H, Nilsson S. Testosterone surge: rationale for GnRH hormone blockers. Urology 2008; 71: 10016
  • 11
    Iversen P, Tyrrell CJ, Kaisary AV et al. Casodex (bicalutamide) 150 mg monotherapy compared with castration in patients with previously untreated non-metastatic prostate cancer: results from two multicentre randomized trials at a median follow-up of 4 years. Urology 1998; 51: 38996
  • 12
    Tyrrell CJ, Iversen P, Tammela T et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU Int 2006; 98: 56372
  • 13
    Molineaux CJ, Sluss PM, Bree MP et al. Suppression of plasma gonadotropins by abarelix: a potent new LHRH antagonist. Mol Urol 1998; 2: 26571
  • 14
    Streda R, Mardesic T, Sobotka V, Tosner J. Long GnRH agonist vs. GnRH antagonist protocol in randomized controlled trial in unselected patients – hormonal and cycle characteristics – pilot study. Ceska Gynekol 2009; 74: 7580
  • 15
    Debruyne F, Gres AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008; 54: 1707
  • 16
    Klotz L, Boccon-Gibod L, Shore ND et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in prostate cancer patients. BJU Int 2008; 102: 15318
  • 17
    Tomera K, Gleason D, Gittelman M et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001; 165: 15859
  • 18
    Koch M, Steidle C, Brosman S et al. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. Urology 2003; 62: 87782
  • 19
    McLeod D, Zinner N, Tomera K et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001; 58: 75661
  • 20
    Teillac P, Debruyne FMJ, Schulman CC, Jonas U, Selvaggi FP, for the ABACAS 1 Study Group. ABACAS 1: a comparison of the eficacay and safety of abarelix versus goserlein plus bicalutamide in patients with advanced or metastatic prostate cancer. A one year randomized open-label multicentre, Phase III trial. Eur Urol 2001; 39 (Suppl. 5): 78
  • 21
    Trachtenberg J, Gittleman M, Steidle C et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002; 167: 16704
  • 22
    Wong SL, Lau DT, Baughman SA, Menchaca D, Garnick MB. Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. Clin Pharmacol Ther 2003; 73: 30411
  • 23
    Debruyne F. GnRH antagonists in the management of prostate cancer. Rev Urol 2004; 6 (Suppl. 7): S2532
  • 24
    Praecis Pharmaceuticals. Abarelix for Injectable Suspension. Prescribing Information. Cambridge, MA: Praecis Pharmaceuticals Inc, 2004
  • 25
    Praecis Pharmaceuticals. Data on file. Praecis Pharmaceuticals Inc, 2009
  • 26
    Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 2002; 301: 95102
  • 27
    Kreis W, Ahmann FR, Jordan VC, De Haan H, Scott M. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation. Br J Urol 1988; 62: 3524
  • 28
    Waxman J, Man A, Hendry WF et al. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J (Clin Res) 1985; 291: 13878